THE STEROID HORMONAL MILIEU OF THE HUHAN FETUS AND
UOTHER AT 16-20 UEEKS OF GESTATION.
The inter-relations of steroid hormone levels in plasma from mothers and their undisturbed fetuses during the second trimester of human pregnancy have not been defined previously. Maternal vein (WV), fetal artery (PA), fetal vein (FV) and amniotic fluid (AP) levels of progesterone (P), 17-OHP, 11 deoxycortisol (S), W C , cortisone (E), cortisol (F), corticosterone (B) and aldosterone (Aldo) were measured in microassays in 12 conscious but sedated mothers and their fetuses undergoing therapeutic termination of pregnancy at 16-20 weeks gestation. The study received the approval of the Hospital Ethical' Committee and maternal consent for the studies was obtained in each case. FA and W samples were obtained by direct vessel puncture through a fetoscope without fetal disturbance. FA levels of F and B were significantly higher (~(0.01) than in PY; W levels of P and E were higher (p<0. Concentrations of FAldo and GAldo were simultaneously measured by specific RIA in 84 samples of human amniotic fluid (AF)collected between 15-34 weeks in normal pregnancies. PAldo was concomitantly determined by RIA on samples obtained at 14.00 hr, after two hours decubitus. PAldo showed a significant rise during pregnancy, its level averaging 134.5 2 10.8 pglml (mean ' SEM) before 20 weeks (n = 62) and 288.2 2 49.2 pg/ml between 20-34 weeks (n=22) {p < 0.01). In AF, the increase of GAldo during the second stage of pregnancy largely exceeded that of FAldo rising from 81.2 ? 5.7 pg/ml to 269.5 2 61.2 pglml and from 84.0 -+ 5.9 pglml to 118.8 ? 11.5 pg/ml for the latter between the 15-20 weeks and 20-34 weeks periods. A significant relationship between AF levels and age of pregnancy could only be detected for GAldo (r= 0.691, p<0.01). Our results agree with patterns of PAldo (Weir et al, 1974 , Ledow et al, 1975 and FAldo (Blankstein et al, 1980 , Sippell et al, 1981 already reported. The increase of GAldo presently described disagrees with its high and stable level reported by Aderjan et a1 (1977) on poorly documented data. Simultaneous determination of F-and G-Aldo shows that the rate of increase of fetal aldosterone production is higher than could be expected from estimation of FAldo alone. Augmentation of GAldo in AF probably expresses both the jncreased contribution of urine to AF and the maturation of renal glycuronoconjugation process. We studied the m l e of AVP in the water metabolism of pretexm infants with a sensitive urinary AVP RIA.Three gmups were studie d.GmupA:16 orally fed infants from 32 to 38 weeks of gestation. GmupB:6 infants with parenteral fluid ahinistration f m 32 to 36 weeks of gestation.GmupC:12 infant~~ventilated for RDS f m m 28 to 36 weeks of gestation with parenteral fluid acfninistration. Gr.A received 5@9 ml/kg on day 1 with daily increasing mounts -up to 169+17 mlfk on day 7 p.o.They had small urine volumes with high osmiality and lost up to 9% weight.AVP was stim~lated by this water loss f m 15.3+4.3pg/ml on day 1 to 36.6+27.2pg/ml on day 3-5.G1.8 received initTally greater fluid volumes i.v. (109+10 ml/kg onday 11 .They pmduced m r e urine with low osrmlality and did not loose weight.AVP was suppressed f m 13.1+11.4pg/ml on day 1 to 5.4+3.5pg/ml on day 2.GrC received on day 1 already 121 +21ml/kg.~he-infants gained weight up to 107.5+6.3% on day 3while -serun Na decreased to 133 ml/l.Urine volume was inadequate low as was urine omlality inadequate high.AVP was 21.0+18.7pg/ml on day 1 and was not suppressable until day 3.There was a significant [p=D.O5lcorrelation between IminApgar scores and AVP as well as Fi02 and AVP on day 1.No significant correlation was found between m a n respiratory pressure and AVP.We conclude,that infants with RDS have a nonosnotic release of AVP and should receive smaller fluid volmes in the first three days of life. A paradoxical Qi response to TRH has been described in consti-. tutional tall'stature. Bromocriptine (BR) therapy has consequently been proposed to reduce adult height prediction in tall but otherwise normal children. This study evaluates the GH response (0-180min) to a single dose (0.2mg) of TRH (n=59) in 11 tall chil-. dren followed prospectively before (Al) and after (A2) 6 months of treatment with BR (5mg/d), while still on therapy, in 9 children of average height (B), 12 with precocious puberty (C), 9 with delayed puberty (D) and 7 with Qi deficiency (E). Peaks of GH 0 5ng/ml) were observed in 92.3% of cases from groups A to D, whereas none occurred in group E. They occurred mainly beyond 120 minutes (57.6%) and were of similar magnitude in groups Al, A2 and B.,In addition, a bifid secretion pattern occurred in 43.5% of cases. In these patients, the early peak was unrelated to stress (normal prolactin). In conclusion, the mode of GH response as well as GH peak amplitude following TRH remain similar in tall and in average height children who are matched for bone age. In group A2, BR failed to modify the GH secretory pattern following TRH injection. The pattern of GH secretion observed after TRH might be the expression of its normal amplified pulsatile secretion mode during puberty and thus be independent of TRH.
L. l
The Endocrine Unit, The Middlesex Hospital, London W1. United Kingdom.
THE MECHANISM OF THE ADOLESCENT GROWTH SPURT INDUCED BY PULSATILE GnRH TREATMENT
We have induced puberty in 26 patients (12M, 14F) using low dose pulsatile CnRH for 0.8 to 1.6 years. Progress was monitored by serial overnight profiles for gonadotrophins, GH and sex steroids at 15 minute intervals. GnRH 2 or 4ugs was administered subcutaneously at night at 90 minute intervals. In order to maintain normal pubertal development, GnRH pulse amp1,itude was progressively increased and/or treatment was administered throughout 24 hrs. We have succeeded in mimicking all the endocrine and clinical events of puberty including the timings of the adolescent growth spurts.
Girls showed early growth acceleration with an increase in GH secretion from the first week of treatment. After breast stage 4 had been attained, GH pulse amplitude varied with the state of ovarian follicular development. By contrast, boys showed a decelerating growth velocity and diminishing GH pulse amplitude at the start of treatment, even though sex steroid secretion increased progressively. When a lOml testicular volume had been attained there was a marked increase in GH pulse amplitude coincident with the pubertal growth spurt. In both sexes GH secretion was modulated by changes in pulse amplitude without alteration in pulse frequency.
These observations explain the differences in timings of the onset of the adolescent growth spurts of girls and boys. 
After completio~i of growth hormone (GH) treatment, 19 patients with isolated "ldlopathlc" growth hormone deficiency (IGHD) arid 15 with post-irradiation growth hormone deficiency (PRGHD) were asked to undergo retesting of GH secretion with an insulln tolerance test and/or an arginine stimulation test. PRGHD patients are those with CNS tumours distant from thehypothalamlcpituitary axis (nz13) or acute lymphatic leukaemia (n=2), who had received cranialorcranospinal irradiation.
All 15 patients with PRGHD remained GH deficient [peak GH level <7mU/1 (n=10) and 7-15mU/1 (n=5)].
However of the 19 retested IGHD patients, 5 (26%) had peak GH responses >15mU/1 (regarded now as transient or false F-IGD) and were indistinguishable from the remainder [~ermanent or true 1-IGHD, peak GH levels <7mU/1 (nz12) and 7-15 mU/1 (n=2)] by pre-treatment anthropometry and post-treatment height SOS, but had a lower first year height velocity (Mean Velocity 5.4cm/yr r0.9 for F-IGHD v 8.7cm/year +1.75 for T-IGHO p<0.01) and height acceleration on treatment (Mean acceleration 2.lcm/yr r1.7 for F-IGHD v 5.2cm/yr r2.3 for T-IGHD p<O.D5).
By current practices 2 F-IGHD patients may have been distinguished by sex-steroid priming.
Thus post-irradiation GH deficiency appears to be permanent but errors of diagnosis in IGHD are common.
